IMNM Stock: Price, Earnings History and SEC Filings
Immunome, Inc. (IMNM) last traded at $18.21, down 0.44% on the latest session and down 15.3% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.65 against an analyst estimate of $-0.51, a miss of 27.5%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
IMNM earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 11, 2026 | $-0.65 | $-0.51 | -27.45% |
| Mar 2026 | May 12, 2026 | $-0.48 | $-0.60 | +20.00% |
| Dec 2025 | Mar 3, 2026 | $-0.75 | $-0.65 | -15.38% |
| Sep 2025 | Nov 6, 2025 | $-0.65 | $-0.57 | -14.04% |
IMNM beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
How IMNM reacts to earnings
Across its last 8 earnings releases, IMNM moved 4.3% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-11 | After close | +6.63% |
| 2026-05-12 | After close | -2.16% |
| 2026-03-03 | After close | +4.55% |
| 2025-11-06 | After close | -1.68% |
| 2025-08-06 | After close | -5.64% |
| 2025-05-12 | After close | -0.38% |
| 2025-03-19 | After close | +1.05% |
| 2025-01-29 | After close | +12.41% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
IMNM financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $7M | -$212M | -$201M | -3060.0% | $-2.43 |
| 2024 | $9M | -$293M | -$118M | -3240.4% | $-5.00 |
| 2023 | $14M | -$107M | -$8M | -761.9% | $-5.38 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for IMNM
- 8-K · Oct 5, 2026Material agreement, Unregistered share sale, Financial statements and exhibits
- 10-Q · Aug 11, 2026
- 8-K · Aug 11, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 12, 2026Shareholder vote
- 10-Q · May 12, 2026
- 8-K · May 12, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 24, 2026
- 10-K · Mar 3, 2026
- 8-K · Mar 3, 2026Results of operations, Financial statements and exhibits
- 8-K · Dec 17, 2025Other events, Financial statements and exhibits
Insider filing activity
IMNM insiders filed 4 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
IMNM news
- Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid TumorsOct 30, 2026 · finance.yahoo.com
- Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026Oct 26, 2026 · finance.yahoo.com
- William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates CoverageOct 21, 2026 · finance.yahoo.com
About Immunome, Inc.
Immunome, Inc. (IMNM) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.